During the celebration of the 50th anniversary of the founding of the Korean Cancer Association, articles published in Cancer Research and Treatment from 2004 to 2023 were assessed based on the subject and design of each study. Based on this analysis, trends in domestic cancer research were inferred and directions were suggested for the future development of Cancer Research and Treatment.

During the celebration of the 50th anniversary of the founding of the Korean Cancer Association, articles published in Cancer Research and Treatment from 2004 to 2023 were assessed based on the subject and design of each study. Based on this analysis, trends in domestic cancer research were inferred and directions were suggested for the future development of Cancer Research and Treatment.

During the celebration of the 50th anniversary of the founding of the Korean Cancer Association, articles published in Cancer Research and Treatment from 2004 to 2023 were assessed based on the subject and design of each study. Based on this analysis, trends in domestic cancer research were inferred and directions were suggested for the future development of Cancer Research and Treatment.

Objective: To determine the preventive effect of changing gadolinium-based contrast agents (GBCAs) to reduce the recurrence of GBCA-associated acute adverse drug reactions (ADRs). Materials and Methods: This retrospective, observational, single-center study—conducted between January 2016 and December 2021—included 238743 consecutive GBCA-enhanced MRI examinations. We focused on a subgroup of patients who experienced acute GBCA-associated ADRs during any of these examinations and subsequently underwent follow-up GBCAenhanced MRI examinations up until July 2023. The follow-up examinations involved either the same (non-change group) or different (change group) GBCAs compared to the ones that initially caused the acute ADR. Baseline participant characteristics, generic profile of the GBCAs, administration of premedication, history of prior ADR to iodinated contrast media, and symptoms of GBCA-associated acute ADRs were retrospectively analyzed. Multivariable logistic regression with generalized estimating equations and propensity score matching were used. Results: A total of 1042 instances of acute ADRs (0.44%; 95% confidence interval [CI]: 0.41%–0.46%) were reported. Threehundred and seventy-three patients underwent GBCA-enhanced MRI examinations after experiencing GBCA-associated acute ADRs within the study period; 31.9% (119/373) reexperienced acute ADRs at any of the follow-up examinations. The ADR recurrence was significantly lower in the GBCA change group than in the non-change group according to multivariable logistic regression (adjusted odds ratio [OR]: 0.35; 95% CI: 0.13–0.90; P = 0.03) and analysis with propensity score matching (14.3% [6/42] vs. 36.9% [31/84], respectively; OR: 0.32, 95% CI: 0.11–0.94; P = 0.04). A history of an ADR to iodinated contrast media (OR: 1.14, 95% CI: 0.68–1.90; P = 0.62) and premedication (adjusted OR: 2.09, 95% CI: 0.93–4.68; P = 0.07) were not significantly associated with GBCA-associated acute ADR recurrence. A separate analysis for recurrent allergic-like hypersensitivity reactions demonstrated similar results (adjusted OR: 0.20, 95% CI: 0.06–0.65; P < 0.01). Conclusion Changing GBCAs may reduce the risk of GBCA-associated acute ADR recurrence.

Background: The emergence of tigecycline-resistant Acinetobacter baumannii has been reported, and the need for tigecycline susceptibility testing in this strain is increasing. However, neither the Clinical & Laboratory Standards Institute, nor the European Commission on Antimicrobial Susceptibility Testing have provided definitive criteria for tigecycline susceptibility testing of A. baumannii. In this study, the disk diffusion method and the minimal inhibitory concentration (MIC) method were com pared to verify conventionally used Food and Drug Administration-identified interpretive criteria to detect tigecycline resistance of A. baumannii. Methods: Forty-four strains of A. baumannii with tigecycline resistance were collected through the Kor-GLASS (Korean Global Antimicrobial Resistance Surveillance System) study in 2022 using the disk diffusion test (DDT). This strain was retested with the MIC method using a Sensititre Gram Negative GN6F AST plate (Thermo Fisher Scientific, USA) to confirm tigecycline resistance. The confirmed strain was subjected to whole genome analysis to elucidate the tigecycline resistance mechanism. Results: Only one of the 44 isolates identified as resistant to tigecycline by the DDT showed resistance with the MIC method, thus the concordance rate of the two methods was 2.3% (1/44). Sequence type 195 strain, carrying bla OXA23 was identified. This strain had no resistance genes of the tetracycline family but had resistance genes to other antimicrobial families. Conclusions Discrepancy of the tigecycline susceptibility test of A. baumannii was identified. To detect tigecycline resistance of A. baumannii, more reliable methods are required.